US FDA clears Akorn's generic CellCept after Form 483 resolved

By Gareth Macdonald

- Last updated on GMT


Related tags Food and drug administration

The US FDA has cleared Akorn Inc. to sell a generic version of the immunosuppressant CellCept made at its plant in Decatur, Illinois.

The drug - mycophenolate mofetil - is the first to be approved since the manufacturing facility on W. Grand Avenue, Decatur passed a US Food and Drug Administration (FDA) re-inspection in December​.

Last summer​ Akorn was issued with a Form 483 after agency inspectors identified a number of problems after an FDA audit.

Akorn welcomed the approaval and predicted that abbreviated new drug applications (ANDAs) for other injectables made at the site would be approved.

CEO Raj Rai told investors the decision “implies that we should now expect to receive approvals for other filings" ​delayed due to the site's compliance status.

Akorn has 90 ANDAs filed with the FDA, however, not all of these are produced at the W. Grand Avenue facility.

ANDA outlook

The US FDA also approved a New Drug Application (NDA) for an anaesthetic called ephedrine sulfate that is made at the Decatur facility.

This ephedrine approval was reflected in Akron's guidance for 2017.

The firm said it will generate revenue of $1.01bn and $1.06bn with new products, including ephedrine, expected to contribute $30m to $60m.

It also predicted it woultwo ephedrine competitors for the remainder of 2017 and forecast that it will hold 30%-35% of the market.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...